港股上市公司荣昌生物（09995.HK）今日盘中大涨6.83%，引发市场关注。截至发稿时，该股报54.600港元/股，成交量933.163万股，换手率4.47%，振幅8.08%。资金面上，该股当日资金流入2.6843亿港元，流出1.57294亿港元，呈现净流入态势。
此次股价上涨主要受益于公司重磅创新药泰它西普获得5年专利补偿的利好消息。据悉，泰它西普的专利权期限将延长至2032年。这不仅延长了公司的专利保护期，也是中国药品专利权期限补偿制度下的成功案例之一，充分体现了荣昌生物在创新药研发领域的实力和市场认可度。
值得注意的是，泰它西普已获批用于治疗重症肌无力等适应症。作为一家专注于研发、生产和销售医药产品的生物技术公司，荣昌生物在行业内具有较强竞争力。此次专利补偿的获得，不仅有利于公司长期发展，也为整个生物医药行业的创新研发注入了信心。在当前生物技术行业整体上涨2.44%的背景下，荣昌生物的表现更加亮眼，显示出投资者对公司未来发展前景的看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.